<div id="readability-page-1"><p>Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) saw some unusual options trading on Wednesday. Investors  acquired 44,799 call options on the company. This represents an increase of approximately 1,415% compared to the typical daily volume of 2,957 call options.</p><h2>Insiders Place Their Bets</h2><p>In other Nuvation Bio news, insider Gary Hattersley sold 100,000 shares of Nuvation Bio stock in a transaction on Monday, October 27th. The shares were sold at an average price of $5.02, for a total transaction of $502,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Dongfang Liu sold 150,000 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the sale, the insider owned 18,000 shares of the company's stock, valued at $140,760. This trade represents a 89.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,000 shares of company stock worth $2,050,800 in the last 90 days. 29.93% of the stock is currently owned by insiders. </p><h2>Institutional Inflows and Outflows</h2><p>Several hedge funds and other institutional investors have recently modified their holdings of NUVB. Highline Wealth Partners LLC acquired a new stake in shares of  Nuvation Bio in the second quarter valued at $25,000.  Rangeley Capital LLC purchased a new position in  Nuvation Bio during the 2nd quarter valued at about $25,000.  Parallel Advisors LLC grew its position in  Nuvation Bio by 51.9% in the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company's stock valued at $28,000 after acquiring an additional 2,597 shares in the last quarter.  Cetera Investment Advisers purchased a new stake in  Nuvation Bio during the second quarter worth about $29,000.  Finally, Captrust Financial Advisors purchased a new stake in  Nuvation Bio during the second quarter worth about $32,000. 61.67% of the stock is currently owned by hedge funds and other institutional investors. </p><h2>Wall Street Analyst Weigh In</h2><p>NUVB has been the subject of a number of analyst reports. HC Wainwright upped their price target on Nuvation Bio from $10.00 to $18.00 and gave the company a &#34;buy&#34; rating in a research report on Thursday, December 11th. Truist Financial  set a $11.00 target price on Nuvation Bio in a research note on Monday, November 24th. Citizens Jmp lifted their price target on Nuvation Bio from $8.00 to $10.00 and gave the stock a &#34;market outperform&#34; rating in a report on Thursday, November 20th. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of Nuvation Bio in a report on Wednesday, October 8th. Finally, Citigroup  restated a &#34;market outperform&#34; rating on shares of Nuvation Bio in a research report on Tuesday, November 4th. One analyst  has rated the stock with a Strong Buy rating, nine have given a Buy rating and one  has given a Sell rating to the company. According to MarketBeat, Nuvation Bio  has an average rating of &#34;Moderate Buy&#34; and an average price target of $10.56.</p><p><b>View Our Latest Stock Report on NUVB</b></p><h2>Nuvation Bio Trading Down 1.7%</h2><p>Shares of NUVB traded down $0.15 during trading on Wednesday, reaching $8.52. 5,172,912 shares of the company traded hands, compared to its average volume of 5,605,226. The stock has a 50-day simple moving average of $5.88 and a 200-day simple moving average of $3.77. The stock has a market cap of $2.92 billion, a PE ratio of -13.30 and a beta of 1.58. Nuvation Bio has a twelve month low of $1.54 and a twelve month high of $8.95. The company has a quick ratio of 8.39, a current ratio of 8.48 and a debt-to-equity ratio of 0.14. </p><p>Nuvation Bio (NYSE:NUVB - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.01. Nuvation Bio had a negative net margin of 813.07% and a negative return on equity of 54.99%. The firm had revenue of $13.12 million for the quarter, compared to analyst estimates of $7.48 million.  On average, analysts anticipate that  Nuvation Bio will post -0.36 earnings per share for the current year. </p><h2>About Nuvation Bio</h2> (Get Free Report)<p>Nuvation Bio Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Nuvation Bio</li><li>The Role Economic Reports Play in a Successful Investment Strategy</li><li>Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish</li><li>Canadian Penny Stocks: Can They Make You Rich? </li><li>Is Tesla Overvalued? 2 Reasons It Might Be a Bargain</li><li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li><li>How These 2 Stocks Won 2025's AI Race—And What's In Store for 2026</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Nuvation Bio Right Now?</h2><p>Before you consider Nuvation Bio, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nuvation Bio wasn't on the list.</p><p>While Nuvation Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

NUVB

<p>Nuvation Bio Inc. (NYSE:NUVB) experienced a significant increase in options trading volume, with 44,799 call options purchased, a 1,415% rise from the average. Insiders sold 320,000 shares worth $2,050,800 in the last 90 days. Hedge funds and institutional investors own 61.67% of the stock. Analysts have mixed ratings, with an average price target of $10.56. The stock traded down 1.7% to $8.52. Nuvation Bio reported a Q3 loss of $0.16 per share, beating estimates by $0.01, with revenue of $13.12 million.</p>

Nuvation Bio Sees Unusually Large Options Volume (NYSE:NUVB)